Intellia Therapeutics (NTLA) said late Wednesday that enrollment in its late-stage study for NTLA-2002 in hereditary angioedema remains on track, with completion expected in Q3 and a Biologics License Application filing planned for H2 next year.
The company also said enrollment in the late-stage trial of nex-z for ATTRv-PN is also progressing well and that it expects to complete the study to support a potential BLA by 2028 and commercial launch by 2029.
Additionally, Intellia said enrollment in its late-stage study of nex-z for ATTR-CM is progressing well as expected.
Shares of the company were down by more than 20% in recent Thursday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。